Show simple item record

[Evidence summary:] Are people who were previously infected with SARS CoV 2 adequately protected following one dose of a COVID 19 vaccine? [v1.0]

dc.contributor.authorClark, Helen
dc.contributor.authorMorgan, Margaret
dc.contributor.authorLeen, Brendan
dc.contributor.authorO'Reilly, Peter
dc.contributor.authorCasey, Geraldine
dc.contributor.authorBeatty, Kenneth
dc.contributor.authorMullane, Paul
dc.contributor.authorWhite, Philippa
dc.date.accessioned2021-08-20T15:27:41Z
dc.date.available2021-08-20T15:27:41Z
dc.date.issued2021-08
dc.identifier.urihttp://hdl.handle.net/10147/630147
dc.descriptionMain Points 1. The WHO recommends that authorized vaccines should be offered regardless of a person's history of symptomatic or asymptomatic SARS CoV 2 infection. 2. 6 months after initial natural infection, available data show that symptomatic reinfection is uncommon. In the event of limited vaccine supply, persons with PCR confirmed SARS CoV 2 infection in the preceding 6 months may choose to delay vaccination until near the end of the 6 month period. 3. Several small recently published and preprint studies show that individuals with evidence of prior SARS CoV 2 infection mount substantially higher antibody responses to the first dose of mRNA vaccines compared with SARS CoV 2 naive individuals; that antibody response to the first vaccine dose in individuals with pre existing immunity is greater than or equal to the titers found in naive individuals after the second dose; and that individuals with prior exposure to SARS CoV 2 demonstrated strong antibody responses to the first dose, but muted responses to the second dose of the vaccine. Among the limitati ons of these findings are small study size and short follow up of study participants. 4. There is limited evidence that immune response decreases with age. 5. Individuals with a history of SARS CoV 2 may also be more likely to experience local and systemic adver se effects (eg fevers, chills, myalgia and fatigue) after a first vaccine dose than SARS CoV 2 naive individuals. This is not a contraindication or precaution to a second dose if receiving a vaccine given as two doses.en_US
dc.language.isoenen_US
dc.publisherHealth Service Executiveen_US
dc.relation.ispartofseriesQ.206en_US
dc.subjectCORONAVIRUSen_US
dc.subjectCOVID-19en_US
dc.subjectVACCINATIONen_US
dc.subjectIMMUNISATIONen_US
dc.subjectRISK FACTORSen_US
dc.title[Evidence summary:] Are people who were previously infected with SARS CoV 2 adequately protected following one dose of a COVID 19 vaccine? [v1.0]en_US
dc.typeOtheren_US
refterms.dateFOA2021-08-20T15:27:41Z


Files in this item

Thumbnail
Name:
Q206 [Evidence Summary] COVID-19 ...
Size:
1.810Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record